middle.news
Starpharma Secures $5.5M Genentech Deal, Advances Radiotheranostics to Clinic
1:21pm on Friday 14th of November, 2025 AEDT
•
Biotechnology
Read Story
Starpharma Secures $5.5M Genentech Deal, Advances Radiotheranostics to Clinic
1:21pm on Friday 14th of November, 2025 AEDT
Key Points
Major $5.5 million upfront payment from Genentech with potential $564 million milestones
Radiopharm Theranostics collaboration initiates first radiopharmaceutical partnership
DEP® HER2 radiotheranostics program advancing to first-in-human trials in 2026
Revenue growth driven by licensing, milestone payments, and product sales
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SPL
OPEN ARTICLE